



Annual General Meeting of Shareholders

TAKARA BIO INC.
June 23, 2020

* This is an English translation from Japanese presentation material.

Consolidated Financial Results for FY2020

(million yen)	FY2020 * Actual	Y on Y		
		Change	Ratio	
Net sales	34,565	▲ 1,275	▲ 3.6%	Net sales Decreased due to former AgriBio business transfer, etc. despite increases in research reagents and contract service
Cost of Sales	13,459	▲ 1,696	▲ 11.2%	Cost of sales • Gross profit Gross profit increased due to improved cost ratio from composition change by items and others
Gross profit	21,105	420	+2.0%	
SG&A expenses	14,830	▲ 390	▲ 2.6%	SG&A expenses R&D expenses decreased due to expenses transfer involved in Gene therapy to partner
Operating profit	6,274	+811	+14.8%	Operating profit Marked new record (Increased for 11 consecutive years)
Ordinary profit	6,347	+682	+12.1%	
Net income attributable to owners of the parent	3,819	+162	+4.4 %	

Results of Medium-Term Management Plan FY2020

Net sales unachieved, but operating profit exceeded original plan

Performance of Medium-Term Plan


(100 million yen)	Actual (20/03)	Original plan (17/05 announced)
Net sales	345	385
Operating profit	62	40

Net sales

Unachieved due to AgriBio business transfer in 2018

Operating profit

Exceeded the original plan by sales growth of research reagents in overseas, CDMO business expansion and licensing revenue in Gene therapy business, etc.



9



Long-Term Management Plan FY2026 ① Vision(Ideal)

Develop bio-drug discovery platform technologies via core businesses of research reagents and scientific instruments and CDMO business, aimed at **becoming a drug discovery company creating new modalities continuously**

